Medidata
Medidata provides a unified platform for clinical trial management, patient engagement, and data analytics, serving pharmaceutical, biotech, and research organizations.
Veeva Clinical is not one product but a suite on Veeva's Vault platform: CTMS, Study Startup, Payments and Site Connect on the operations side; EDC, data-quality tooling (DQS) and eCOA on the data side; and RIM, Safety and Quality applications around them. For a sponsor already standardized on Vault, that breadth is the point — one platform, one data model, one vendor. The trade-offs are equally structural. Pricing is not publicly listed; every engagement starts with sales. Implementation involves configuration rather than self-serve setup, and the total cost of ownership includes the change management of moving sites and CROs onto your instance. Sponsors and CROs who want a different delivery model — decentralized-first, data-and-services, or a platform that arrives with forward-deployed engineers — evaluate these four.
Closest like-for-like platform rival: Medidata, the other unified clinical trial suite. Best for decentralized and hybrid trials: Medable, built around eCOA, eConsent and devices. Best when you want data and services, not just software: IQVIA. Most different model: Huma, a regulated platform with ready-to-deploy clinical apps. Stay with Veeva Clinical when the Vault suite is already your system of record and the configuration investment is sunk and working. Compare Medidata first for a suite-for-suite move. Choose Medable when decentralized or hybrid design is driving the change, IQVIA when what you actually need is data and delivery capacity rather than another platform, and Huma when you want a governed platform plus engineers who build on it with you. In every case, budget for implementation and validation — in clinical systems, the licence is rarely the expensive part.
Medidata provides a unified platform for clinical trial management, patient engagement, and data analytics, serving pharmaceutical, biotech, and research organizations.
The other unified platform. Medidata, part of Dassault Systèmes, organizes its offer in three layers: study experience (CTMS, eTMF, financial management, protocol optimization, feasibility, grants management, site payments), patient experience (eCOA, consent, the myMedidata portal, a diversity program, registries), and data experience (real-world data, a Synthetic Control Arm, and site-performance and feasibility analytics). Medidata Plus is positioned as the AI-native foundation under all three. If your reason for leaving Veeva is vendor strategy rather than suite shape, Medidata is the direct comparison — same breadth ambition, different platform heritage. Our listing does not carry its pricing or compliance detail, so verify both in evaluation rather than assuming parity.
Medable is a clinical trial platform that unifies eCOA, eConsent, sensors, and device data with a purpose-built AI agent platform for GxP-compliant trial operations.
The decentralized-first platform. Medable is built for decentralized and hybrid trials: eCOA, eConsent, sensors, and both provisioned devices and BYOD in one participant experience. Its Agent Platform is purpose-built for clinical development in a GxP context — agentified eCOA, Medable Studio for study build, AI translation — with human-in-the-loop controls and every automated action logged, explainable and auditable. The company reports eCOA adherence above 90% across a 70-plus-site master protocol and Studio cutting build time from weeks to one business day; treat those as company-reported results from its own deployments. Its stated "1:1:1 vision" (one day to start, one day to enroll, one year to conduct) is an aspiration, not a current SLA. Compliance alignment spans HIPAA, GDPR, ISO, FDA 21 CFR Part 11 and ICH E6(R2) GCP. Pricing is not publicly disclosed. Choose Medable when the trial design itself is the reason to move.
IQVIA provides life sciences organizations with data, analytics, and technology to accelerate innovation, improve patient outcomes, and bring treatments to market faster.
The data-and-services route. IQVIA is not a self-serve software suite at all: it is a global life-sciences data, technology and services provider spanning R&D, commercialization, real-world evidence, safety and regulatory, and patient centricity. Its technology layer includes IQVIA AI — with a Field Force Agent for HCP engagement — and an NLP platform that turns unstructured text into structured data at enterprise scale; the vendor claims it can expedite medical record review by 10x to 100x, which is a vendor claim to test against your own corpus. Sponsors choose IQVIA when the gap is not a missing module but missing capacity: data assets, therapeutic expertise and people who run the work. That makes it a complement-or-replace decision rather than a like-for-like swap — scope it as a services engagement, not a licence migration.
Huma provides a regulated operating system that lets healthcare, life sciences, and government organizations build, deploy, and scale AI-powered clinical and operational software on a single governed platform.
The regulated-platform outsider. Huma describes itself as a regulated operating system for AI across healthcare, life sciences and government: a governed, unified data model, the Huma Cloud Platform with a library of ready-to-deploy clinical applications — including a dedicated clinical trials product, alongside primary care, secondary care and public health apps — plus Huma Workspace and Huma Intelligence. Unusually, it sends forward-deployment engineers to build customer-specific capabilities, and its regulatory engine is designed to turn capabilities into cleared products in weeks; the company is candid that specific clearances vary by region and are not detailed on its homepage. It reports more than 100 apps built and roughly 100 million patients supported — company-reported scale figures. Pricing is not published; engagement starts with a demo. Huma fits sponsors and health systems that want a configurable platform with engineering attached, rather than a fixed clinical suite.
Veeva does not publicly list pricing for its clinical applications; engagements are quoted by sales and depend on which Vault applications you license. The same is true of Medidata, Medable, IQVIA and Huma — none publishes prices — so compare implementation scope, validation effort and per-study costs in a structured RFP.
Medable is the decentralized-first option here, with eCOA, eConsent, sensors and BYOD unified in one platform and Part 11 / GCP alignment stated on its listing. Medidata also covers eCOA and consent within its patient-experience layer, so the deciding factor is usually whether decentralization is the core design or one module among many.
Not like-for-like. IQVIA is primarily a data and services provider with technology components, whereas Veeva Clinical is a software suite you run. Some sponsors use IQVIA services alongside or instead of internal platform operations — treat it as an operating-model decision, not a module swap.
At minimum, expect alignment with FDA 21 CFR Part 11 for electronic records and signatures and ICH E6 GCP, plus HIPAA and GDPR where participant data flows. Medable states all of these on its listing; Veeva, Medidata, IQVIA and Huma should be asked for their current attestations directly, since our listings do not publish them.